Results 101 to 110 of about 214,511 (232)

Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden

ChemFoodChem, Volume 2, Issue 3, September 2026.
ABSTRACT Fungal antimicrobial resistance (AMR) is a growing concern for world health caused by an increase in multidrug‐resistant infections, an increase in environmental reservoirs, and the ineffectiveness of current antifungal treatments. Fungal infections continue to be largely excluded from AMR initiatives while causing over 1.6 million deaths ...
Bikash Baral
wiley   +1 more source

The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis

ClinicoEconomics and Outcomes Research, 2015
Habip Gedik Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydani Training and Research Hospital, Istanbul, Turkey Objective: The aim of this study is to analyze the expenditures related to the use of antifungal drugs
Gedik H
doaj  

Current Evidence of Antifungal Prophylaxis and Therapy in Pediatric Patients

Pediatric Reports, 2011
Invasive fungal infections (IFI) are an important complication in pediatric haematological and oncological patients who undergo intensive chemotherapy for leukemia, solid tumour at advanced stage or relapsed, and hematopoietic stem cell transplantation. The incidence of IFI is lower than bacterial infection but mortality rate remains high.
M. Giacchino, G.M. Milano, F. Carraro, S. Bezzio, A. Pegoraro, AVERSA, Franco, S. Cesaro   +6 more
openaire   +6 more sources

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients.

, 2001
Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%
Viscoli, Claudio, Paesmans, Marianne, Glauser, Michel, Klastersky, Jean, Viscoli, C., International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer, Paesmans, M., Sanz, M., Klastersky, J., Martino, Pietro, Martino, P., Sanz, Miguel A, Glauser, M., Castagnola, E.   +13 more
core   +1 more source

Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people [PDF]

, 2018
BackgroundCryptococcal disease remains one of the main causes of death in HIV-positive people who have low cluster of differentiation 4 (CD4) cell counts.
Johnson, Samuel, Rutherford, George W, Eshun‐Wilson, Ingrid, Eshun-Wilson, Ingrid, Awotiwon, Ajibola A, Ajibola A Awotiwon, Graeme Meintjes, Meintjes, Graeme, Samuel Johnson, Rutherford, George E, George W Rutherford, Ingrid Eshun-Wilson   +11 more
core   +1 more source

Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Patients with high‐risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) continue to face a substantial risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), which remains a leading cause of treatment failure.
Cuicui Lyu, Tianle Xie, Yedi Pu, Xianshuang Luan, Xia Xiao, Mingfeng Zhao, Hairong Lyu   +6 more
wiley   +1 more source

Prophylactic use of liposomal amphotericin B in children and adolescents undergoing allogeneic hematopoietic cell transplantation: A 10-years single center experience

EJC Paediatric Oncology
Background: Azoles are recommended as antifungal prophylaxis in decreasing the incidence of invasive fungal disease (IFD) in high-risk patients in pediatric oncology, including patients receiving allogeneic hematopoietic cell transplantation (HCT ...
Laura G.Y. Rotte, Coco C.H. de Koning, Yvette G.T. Loeffen, Marc B. Bierings, Jaap Jan Boelens, Caroline A. Lindemans, Tom F.W. Wolfs   +6 more
doaj   +1 more source

Real‐Life Study on Gilteritinib‐Related Infections (GilteRInf): An Italian SEIFEM Study

American Journal of Hematology, Volume 101, Issue 10, Page 2672-2676, October 2026.
Elisa Buzzatti, Irene Terrenato, Martina Tomassi, Federica Lessi, Sara Pezone, Cristina Papayannidis, Gianluca Martini, Fabio Forghieri, Luana Fianchi, Martina Quattrone, Nicola Fracchiolla, Claudio Fozza, Michela Abbenante, Anna Lina Piccioni, Davide Facchinelli, Claudia Maria Basilico, Caterina Buquicchio, Nicola Di Renzo, Monica Piedimonte, Maria Giovanna Cefalo, Daniele Armiento, Adriano Venditti, Alessandro Busca, Francesco Marchesi, Maria Ilaria Del Principe, Livio Pagano   +25 more
wiley   +1 more source

Volumetric Microsampling for Patient‐Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala, Abbie D. Leino, Nathaniel J. Rhodes, Kevin J. Downes, Marc H. Scheetz, Manjunath P. Pai   +5 more
wiley   +1 more source